Mizuho Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $179.00

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target lifted by Mizuho from $145.00 to $179.00 in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. UBS Group raised their price […]

Related Keywords

Canada ,New Jersey ,United States ,Sarepta ,Stephen Mayo ,Royal Bank ,Sarepta Therapeutics Company Profile ,Sarepta Therapeutics Inc ,Securities Exchange Commission ,Vanguard Group Inc ,Investment Management ,Capula Management Ltd ,Citigroup ,Jersey Common Pension Fund ,Sarepta Therapeutics ,Free Report ,Moderate Buy ,Get Free Report ,Director Stephen Mayo ,Exchange Commission ,Director Kathryn Jean Boor ,Mahoney Asset Management ,Management Ltd ,Sarepta Therapeutics Daily ,